MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
The acquisition will bolster MedImmune’s oncology pipeline by obtaining multiple early-stage assets for its immune-mediated cancer therapy (IMT-C) portfolio, including ...





